Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)
This study is currently recruiting participants.
Verified February 2013 by SOLTI Breast Cancer Research Group
Sponsor:
SOLTI Breast Cancer Research Group
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier:
NCT01669252
First received: August 9, 2012
Last updated: February 11, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2017 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |